In meta-analyses of rare events, it can be challenging to obtain a reliable estimate of the pooled effect, in particular when the meta-analysis is based on a small number of studies. Recent simulation studies have shown that the beta-binomial model is a promising candidate in this situation, but have thus far only investigated its performance in a…

Population adjustment methods such as matching-adjusted indirect comparison (MAIC) are increasingly used to compare marginal treatment effects when there are cross-trial differences in effect modifiers and limited patient-level data. MAIC is based on propensity score weighting, which is sensitive to poor covariate overlap and cannot extrapolate…

Matching-adjusted indirect comparison (MAIC) enables indirect comparisons of interventions across separate studies when individual patient-level data (IPD) are available for only one study. Due to its similarity with propensity score weighting, it has been speculated that MAIC can be combined with outcome regression models in the spirit of…

Drug repurposing refers to the process of discovering new therapeutic uses for existing medicines. Compared to traditional drug discovery, drug repurposing is attractive for its speed, cost, and reduced risk of failure. However, existing approaches for drug repurposing involve complex, computationally-intensive analytical methods that are not…

Standard meta-analysis methods are vulnerable to bias from incomplete reporting of results (both publication and outcome reporting bias) and poor study quality. Several alternative methods have been proposed as being less vulnerable to such biases. To evaluate these claims independently we simulated study results under a broad range of conditions…

It is now widely accepted that the standard inferential toolkit used by the scientific research community--null-hypothesis significance testing (NHST)--is not fit for purpose. Yet despite the threat posed to the scientific enterprise, there is no agreement concerning alternative approaches for evidence assessment. This lack of consensus reflects…

Network meta-analysis (NMA) is gaining popularity for comparing multiple treatments in a single analysis. Generalized linear mixed models provide a unifying framework for NMA, allow us to analyze datasets with dichotomous, continuous or count endpoints, and take into account multiarm trials, potential heterogeneity between trials and network…

Meta-analyses of clinical trials targeting rare events face particular challenges when the data lack adequate numbers of events for all treatment arms. Especially when the number of studies is low, standard random-effects meta-analysis methods can lead to serious distortions because of such data sparsity. To overcome this, we suggest the use of…

Heterogeneity in meta-analysis is most commonly estimated using a moment-based approach described by DerSimonian and Laird. However, this method has been shown to produce biased estimates. Alternative methods to estimate heterogeneity include the restricted maximum likelihood approach and those proposed by Paule and Mandel, Sidik and Jonkman, and…

Bayesian statistical approaches to mixed treatment comparisons (MTCs) are becoming more popular because of their flexibility and interpretability. Many randomized clinical trials report multiple outcomes with possible inherent correlations. Moreover, MTC data are typically sparse (although richer than standard meta-analysis, comparing only two…

When performing a meta-analysis unexplained variation above that predicted by within study variation is usually modeled by a random effect. However, in some cases, this is not sufficient to explain all the variation because of outlier or unusual studies. A previously described method is to define an outlier as a study requiring a higher random…